Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)

Purpose: NRG Oncology conducted a phase II trial to assess the antitumor activity and tolerability of copanlisib, a selective inhibitor of PIK3CA, in persistent or recurrent endometrial carcinoma harboring hotspot PIK3CA mutations. Patients and methods: Eligible patients had endometrial cancer with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Alessandro D. Santin, Virginia Filiaci, Stefania Bellone, Elena S. Ratner, Cara A. Mathews, Guilherme Cantuaria, Camille C. Gunderson, Teresa Rutledge, Barbara M. Buttin, Heather A. Lankes, Michael Frumovitz, Samir N. Khleif, Warner K. Huh, Michael J. Birrer
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020-02-01
Colecção:Gynecologic Oncology Reports
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2352578919301213
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados